Key Takeaways

Dapagliflozin improved metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis in a randomized trial in China.

The study included younger patients who were predominantly male with a lower BMI, lower prevalence of type 2 diabetes, and less fibrosis than other trials.

Currently, there's only one FDA-approved treatment for MASH.

An SGLT2 inhibitor helped improve metabolic dysfunction-associated steatohepatitis (MASH) in people with or without type 2 diabetes, a randomized trial in China found.

In 154 adults with biopsy-diagnosed MASH, improvement without worsening fibrosis occurred in 53% of people treated with dapagliflozin (Farxiga) versus 30% on placebo (risk ratio [RR] 1.73, 95% CI 1.16-2.58, P =0.006), reported Huijie Zhang, MD, PhD, of Sou

See Full Page